Skip to main content

Table 4 Baseline data analysis of 1245 patients with different surgical mode

From: Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

Variables

BCS (%)

Mastectomy (%)

Radical Mastectomy (%)

χ2

P-value

Race

     

White

297 (78.0%)

204 (80.0%)

467 (76.7%)

  

Black

57 (15.0%)

38 (14.9%)

95 (15.6%)

2.12

0.714

Other

27 (7.0%)

13 (5.1%)

47 (7.7%)

  

Age

     

 ≤ 35

13 (3.4%)

16 (6.3%)

38 (6.2%)

  

35 < age < 60

181 (47.5%)

132 (51.8%)

318 (52.2%)

8.373

0.079

 ≥ 60

187 (49.1%)

107 (42.0%)

253 (41.5%)

  

Grade

     

1

34 (8.9%)

20 (7.8%)

45 (7.4%)

6.528

0.163

2

173 (45.4%)

129 (50.6%)

258 (42.4%)

  

3–4

174 (45.7%)

106 (41.6%)

306 (50.2%)

  

Laterality

     

Left

209 (54.9%)

130 (51.0%)

317 (52.1%)

1.115

0.573

Right

172 (45.1%)

125 (49.0%)

292 (48.0%)

  

Marital

     

Married

206 (54.1%)

138 (54.1%)

318 (52.2%)

  

Unmarried

175 (45.9%)

117 (45.9%)

291 (47.8%)

0.438

0.803

Ethnic origin

     

Spanish-Hispanic-Latino

43 (11.3%)

23 (9.0%)

70 (11.5%)

1.205

0.547

Non-Spanish-Hispanic-Latino

338 (88.7%)

232 (91.0%)

539 (88.5%)

  

Histology

     

IDC

326 (85.6%)

201 (80.0%)

49 (77.0%)

5.163

0.076

Non-IDC

55 (14.4%)

54 (20.0%)

113 (33.0%)

  

T stage

     

T1

91 (23.9%)

21 (8.2%)

41 (6.7%)

158,845

 < 0.001

T2

22 (58.3%)

109 (42.7%)

238 (39.10%)

  

T3

37 (9.7%)

59 (23.1%)

146 (24%)

  

T4

31 (8.1%)

66 (25.9%)

184 (30.20%)

  

N stage

     

N0

126 (33.1%)

52 (20.4%)

30 (4.9%)

  

N1

133 (34.9%)

124 (48.6%)

206 (33.80%)

192.317

 < 0.001

N2

67 (17.6%)

41 (16.10%)

153 (25.10%)

  

N3

55 (14.4%)

38 (14.90%)

220 (36.10%)

  

Radiation

     

Yes

22 (60.1%)

124 (48.6%)

351 (57.60%)

  

No

15 (39.9%)

131 (51.40%)

258 (42.40%)

8.765

0.012

Chemotherapy

     

Yes

20 (54.9%)

171 (69.50%)

423 (67.10%)

  

No

17 (45.1%)

84 (30.50%)

186 (32.90%)

22.744

 < 0.001

Subtype

     

ER + /HER2−

276 (72.4%)

177 (69.4%)

416 (68.3%)

  

ER + /HER2 + 

54 (14.2%)

34 (13.3%)

101 (16.6%)

6.514

0.368

HER2 + 

15 (3.9%)

11 (4.3%)

35 (5.7%)

  

TNBC

36 (9.4%)

33 (12.9%)

57 (9.4%)

  

ER

     

Positive

329 (86.4%)

207 (81.2%)

514 (84.4%)

3.101

0.212

Negative

52 (13.6%)

48 (18.8%)

95 (15.6%)

  

PR

     

Positive

281 (73.8%)

176 (69.0%)

429 (70.4%)

1.97

0.373

Negative

100 (26.2%)

79 (31.0%)

180 (29.6%)

  

HER2

     

Positive

69 (18.1%)

45 (17.6%)

136 (22.3%)

3.786

0.151

Negative

312 (81.9%)

210 (82.4%)

473 (77.7%)

  
  1. ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer